HIV medications: Difference between revisions

Revision as of 10:18, 28 July 2020

Class	Examples	Description
Nucleoside reverse-transcriptase inhibitor (NRTI)	tenofovir, emtricitabine, abacavir	Nucleoside/nucleotide analogues that get incorporated into viral DNA by reverse transcriptase, causing missense or non-sense mutations. The backbone of HIV treatments, with a high barrier to resistance.
Non-nucleoside reverse-transcriptase inhibitor (NNRTI)	efavirenz	Actively inhibit reverse transcriptase at its active site. Resistance develops with a single point mutation.
Protease inhibitor (PI)	dirunavir	Inhibits protease, which is required for processing proteins in the creation of the virion. Causes a metabolic syndrome.
Integrase strand transfer inhibitor (INSTI)	raltegravir, dolutegravir, bictegravir	Extremely potent with few side effects. Take separate from PPIs etc.
Fusion inhibitor
CCR5 entry inhibitor	maraviroc	Blocks entry of HIV into CD4 cells.
CD4-mAb	ibalizumab

Medication	Abbr	Class	Notes
lamivudine	3TC	NRTI
emtricitabine	FTC	NRTI
tenofovir disoproxol fumarate	TDF	NRTI
tenofovir alafenamide	TAF	NRTI	Fewer renal and bone effects.
zidovudine	AZT	NRTI
abacavir	ABC	NRTI	Need to check HLA-B*5701 before starting therapy.
efavirenz	EFZ	NNRTI
nevirapine	NVP	NNRTI
rilpivirine	RPV	NNRTI	Take with meal, not with PPI.
doravirine	DOR	NNRTI
lopinavir/ritonavir	LPV/r	PI	GI side effects.
darunivir	DRV	PI
ritonavir	RTV	PI
dolutegravir	DTG	INSTI	Increases metformin levels. Avoid in pregnancy.
elvitegravir/cobicistat	EVG/c	INSTI	Requires booster that has drug interaction.
raltegravir	RAL	INSTI	First INSTI. BID dosing. Only INSTI that can be used in pregnancy.
bictegravir	BIC	INSTI
cabotegravir	CAB	INSTI	Long-acting injectable available.
ibalizumab			CD4-receptor antibody.

Brand name	NRTIs	Non-NRTI	First-line?	Notes
Atripla	tenofovir disoproxil fumarate / emtricitabine	efavirenz (NNRTI)	No	Older regimen. Neuropsychiatric symptoms, possibly including suicide.
Biktarvy	tenofovir alafenamide / emtricitabine	bictegravir (INI)	Yes
Complera	tenofovir disoproxil fumarate / emtricitabine	rilpivirine (NNRTI)	No	Avoid with viral loads (>100,000) or low CD4 (<200). Pill must be taken with food (>400kcal) and without PPIs.
Delstrigo	tenofovir disoproxil fumarate / lamivudine	doravirine (NNRTI)	No
Dovato	emtricitabine	dolutegravir (INI)	Yes	Two-medication regimen
Genvoya	tenofovir alafenamide / emtricitabine	elvitegravir/cobicistat (INI)	No	See Stribild, above.
Odefsey	tenofovir alafenamide / emtricitabine	rilpivirine (NNRTI)	No
Stribild	tenofovir disoproxil fumarate / emtricitabine	elvitegravir/cobicistat (INI)	No	Includes a P450 inhibitor to boost elvitegravir levels, with resultant drug-drug interactions. Avoid if CrCl <70.
Symfi	tenofovir disoproxil fumarate / emtricitabine	efavirenz (NNRTI)	No
Symtuza	tenofovir alafenamide / emtricitabine	darunavir/cobicistat (PI)	No
Triumeq	abacavir / lamivudine	dolutegravir (INI)	Yes	Highest barrier to resistance. Need to test for HLA-B5701 allele before starting. Avoid in hepatitis B coinfection.

@@ Line 10: / Line 10: @@
 | Nucleoside/nucleotide analogues that get incorporated into viral DNA by reverse transcriptase, causing missense or non-sense mutations. The backbone of HIV treatments, with a high barrier to resistance.
 |-
+| Non-nucleoside reverse-transcriptase inhibitor (NNRTI)
-| Non-NRTI
 | [[efavirenz]]
 | Actively inhibit reverse transcriptase at its active site. Resistance develops with a single point mutation.